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A B S T R A C T
Background: Infections caused by drug-resistant Gram-negative bacteria (GNB) are increasing
worldwide and as a result, the selection of appropriate empiric antibiotics (ATBs) has been made
increasingly difﬁcult. The present study aimed to identify optimized dosing regimens of intravenous (IV)
ATBs, deﬁned by cumulative fraction response (CFR), against E. coli (EC), K. pneumoniae (KP), P. aeruginosa
(PA), and A. baumannii (AB) at 2,300-bed University Hospital.
Materials and Methods: The minimum inhibitory concentrations (MIC) of EC, KP, PA, and AB from clinical
specimens, 250 each, were determined. Pharmacodynamic proﬁling using Monte Carlo Simulation was
performed for standard, high dosage, and prolonged infusions (PI) of ceftriaxone, cefepime, ceftazidime,
imipenem, meropenem, and doripenem. A CFR of 90% was targeted as providing a sufﬁciently high ATB
exposure.
Results: When considering the Enterobacteriaceae, the % susceptible for the cephalosporins ranged from
60% for ceftriaxone to 86% for cefepime, as a result only the 2 g q8 h regimens of ceftazidime and
cefepime provided high CFRs. In contrast, all the carbapenems had % susceptible and CFRs 90% for EC
and KP. While cefepime and ceftazidime demonstrated higher % susceptibility (82-83%) for PA relative to
that of the carbapenems (61-69%) only doripenem 2 g q8 h (4 h PI) achieved an optimal CFR (92%) against
this organism. Due to the MIC proﬁles and dismal susceptibilities of AB (16-22%), none of the regimens
studied achieved CFRs > 65%.
Conclusions: The pharmacodynamic proﬁling undertaken in the current study provides insights that
allow prescribers to select more appropriate empirical antibiotic regimens for the treatment of infection
caused by these common GNB pathogens at this Thai hospital. While higher doses and PI of b-lactams
improve exposures against EC, KP and PA, this approach will not sufﬁciently enhance their potency
against AB, thus alternative therapies should be considered for this organism.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Antibiotic-resistant bacteria are increasing worldwide. In Asia,
inclusive of Thailand, multidrug-resistant (MDR) Gram-negative
bacteria such as Pseudomonas aeruginosa, Acinetobacter baumannii,
Escherichia coli, and Klebsiella pneumoniae, are the most problem-
atic causative pathogens of hospital-acquired infection.1,2 The* Corresponding author. Center of Anti-Infective Research and Development,
Hartford Hospital, 80 Seymour Street, Hartford, CT, USA 06102. Tel.: +860 972 3941;
fax: +860 545 3992.
E-mail address: david.nicolau@hhchealth.org (D.P. Nicolau).
http://dx.doi.org/10.1016/j.ijid.2016.03.020
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).common site of infection is hospital-acquired/ventilator-associat-
ed pneumonia (HAP/VAP). The study conducted by the Interna-
tional Nosocomial Infection Control Consortium from January
2004 through December 2009 in 422 intensive care units (ICU) of
36 countries in Latin America, Asia, Africa, and Europe reported the
frequency of resistance of P. aeruginosa isolates to imipenem was
47.2%, K. pneumoniae isolates to ceftazidime was 76.3%, and E. coli
isolates to ceftazidime was 66.7%.3 The authors also mentioned
that the higher rate of resistant Gram-negative bacteria in these
studied countries was higher than the resistance rate in the ICU of
United States. Without the appropriate empirical antibiotics for
the treatment of MDR bacterial infections, the morbidity and
mortality consequences are obvious. The resistance of theseciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1




CLT (L/h) Vc (L) K12 (h
1) K21 (h
1)
Ceftriaxone 2.48 (0.7) 5.9 (1.3) 2.58 (1.4) 1.02 (0.5)
Ceftazidime 5.57 (1.9) 4.67 (1.2) 4.99 (3.1) 2.2 (0.8)
Cefepime 6.04 (0.4) 22.97 (15.6) 11.2 (8.1) 35.63 (19.5)
Imipenem 10.0 (2.1) 8.89 (4.8) 1.35 (0.9) 1.83 (1.3)
Meropenem 13.96 (8.9)b 13.25 (4.9) 1.55 (0.6) 1.48 (0.3)
Doripenem 14.5 (23.6)c 8.29 (0.9) 1.34 (1.0) 1.05 (1.1)
CLT; total body clearance, Vc; volume of distribution in the central compartment,
K12; transfer rate constant from the central compartment to the peripheral
compartment, K21; transfer rate constant from the peripheral compartment to the
central compartment.
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the failure of treatment. Chung DR, et al., focused on HAP and VAP
cases in Asian countries, and demonstrated that the major bacterial
isolates were Acinetobacter spp., P. aeruginosa, Staphylococcus
aureus, and K. pneumoniae. The study showed high rates of drug-
resistant i.e.; imipenem resistance rates of Acinetobacter spp. and P.
aeruginosa were 67.3% and 27.2%, respectively and multidrug-
resistant rates were 82% and 42.8% while extensively drug-
resistant rates were 51.1% and 4.9%. All-cause mortality rate was
38.9% and the discordant initial empirical antimicrobial therapy
increased the likelihood of pneumonia-related mortality.4
The current study aimed to explore the optimal dosing
regimens of b-lactam antibiotics (ATBs) against P. aeruginosa, A.
baumannii, E. coli, and K. pneumoniae from clinical isolates of Siriraj
Hospital, the University Hospital in Thailand, according to
susceptibility pattern and MIC distribution.
2. Materials and Methods
In Siriraj Hospital, 2300-bed University Hospital, there were
83,747 in-patient admissions per year (20% was patients of the
internal medicine department and 21% was patients of the urgical
department). These 2 departments had major hospital-acquired
infection complications from Gram-negative bacteria especially E.
coli, K. pneumoniae, P. aeruginosa and A. baumannii.
2.1. Microbiology
A total of 1,000 Gram-negative isolates, 250 each (E. coli, K.
pneumoniae, P. aeruginosa and A. baumannii) collected between
January 2011 and January 2012 from both medical and surgical
patients across the institutional care units were analyzed in the
present study. The organisms were collected according to the type
of infection, which primarily included bloodstream infection, pus,
body ﬂuid infection and respiratory infection. Each clinical
specimen was processed at the microbiology laboratory, Siriraj
Hospital, according to standard microbiology procedures and
cultured using 5% (v/v) sheep blood agar, chocolate agar and
MacConkey agar, where appropriate. The organisms were identi-
ﬁed by using the Vitek 21 system (bioMe´rieux, Missouri, USA).
MICs of 6 ATBs, ceftriaxone (CRO), ceftazidime (CAZ), cefepime
(FEP), doripenem (DOR), imipenem (IPM) and meropenem (MEM),
were determined by E-test (bioMe´rieux). CRO was not tested for AB
and PA. The quality control of MIC testing was performed using the
reference strains E. coli ATCC 35218 and P. aeruginosa ATCC
27853 according to Clinical and Laboratory Standards Institute
(CLSI).5 MIC50 and MIC90 were determined and susceptibility was
interpreted based on CLSI breakpoints5 where applicable.
2.2. Antimicrobials
As a result of escalating resistance for these common Gram-
negative bacteria in our hospital setting, the appropriateness of the
commonly utilized b-lactam regimens such as ceftriaxone 2 g
every 24 hours, ceftazidime 1 g every 8 hours (0.5-hour infusion),
cefepime 2 g every 12 hours (0.5-hour infusion), imipenem 0.5 g
every 8 hours (0.5-hour infusion), meropenem 1 g every 8 hours
(0.5-hour infusions), and doripenem 0.5 g every 8 hours (1-hour
infusion) for empirical treatment was questioned. Therefore for the
purposes of deﬁning the most optimal regimen of these b-lactams
against the target pathogen, the following pharmacodynamic
proﬁling assessments were undertaken with a variety of antibiotic
regimens:
 ceftriaxone 1 g every 24 hours (0.5-hour infusion)
 ceftriaxone 2 g every 24 hours (0.5-hour infusion) ceftazidime 1 g every 8 hours (0.5-hour and 3-hour infusion)
 ceftazidime 2 g every 8 hours (0.5-hour infusion)
 cefepime 2 g every 12 hours (0.5-hour infusion)
 cefepime 2 g every 8 hours (0.5-hour and 3-hour infusion)
 doripenem 0.5 g every 8 hours (1-hour and 4-hour infusions)
 doripenem 1 g every 8 hours (1-hour and 4-hour infusions)
 doripenem 2 g every 8 hours (1-hour and 4-hour infusions)
 imipenem 0.5 g every 8 hours (0.5-hour infusion)
 imipenem 0.5 g every 6 hours (0.5-hour)
 imipenem 1 g every 8 hours (0.5-hour and 3-hour infusions)
 meropenem 1 g every 8 hours (0.5-hour and 3-hour infusions)
 meropenem 2 g every 8 hours (0.5-hour and 3-hour infusions)
2.3. Pharmacokinetic Model
Steady-state exposures were determined for each antibiotic
regimen using serum pharmacokinetic (PK) parameters obtained
from published population pharmacokinetic studies of infected
and/or critically-ill patients as shown in Table 1.6–11 While more
recent references could have been selected, we have made use of
the citations noted because the newer studies provide similar PK
proﬁles as such incorporation of newer data would not substan-
tially change the interpretation of the PD proﬁles. Thus the outputs
from the current MCS are contemporary despite older PK data as it
is not the PK proﬁle that changes over time but the susceptibility of
the pathogen under study. Moreover, we have chosen to use the
previously utilized PK data so that comparisons could be made to
our previously published work and highlight the importance of the
changing MIC distribution of the organism populations. The
methodology used to simulate steady-state antibacterial expo-
sures has been previously described in the published study by
DeRyke CA, et al.12
2.4. Monte Carlo Simulation
A 5,000 patient Monte Carlo simulation (Crystal Ball 7;
Decisioneering Inc., Denver, CO) was performed for each regimen,
and the probability of a simulated patient achieving the
pharmacodynamic target, referred to as probability of target
attainment (PTA), was calculated over a range of doubling MICs
between 0.008 and  64 mg/L. Pharmacodynamic targets were
deﬁned as fT > MIC of at least 50% of the dosing interval for
cephalosporins and fT > MIC of at least 40% of the dosing interval
for carbapenems13 (imipenem, meropenem, and doripenem).
Probability of target attainment (PTA)* for each regimen was
used to calculate the cumulative fraction of response (CFR)** for
each antibiotic regimen against the bacteria population as
previously described.12 A CFR of at least 90% for a regimen was
deﬁned as optimal against that bacterial population.
Table 3
The susceptibility of antibiotics against E. coli, K. pneumoniae, P. aeruginosa, and A.
baumannii (250 isolates for each organism)
Organisms % susceptible to antimicrobial agents
DOR MEM IPM FEP CAZ CRO
K. pneumoniae 98.8 98.4 97.6 86 69.2 67.2
E. coli 99.6 99.6 99.6 84.8 74.4 60.4
P. aeruginosa 68.8 62 61 82.7 82.4 NA
A. baumannii 17.2 16.4 16 21.6 NA NA
DOR; doripenem, MEM; meropenem, IPM; imipenem, FEP; cefepime, CAZ;
ceftazidime, CRO; ceftriaxone.
Table 4
Summary of cumulative fraction of response (CFR) for selected intravenous




EC KP AB PA
ceftriaxonec
1g q24h 60.1 66.5 NA NA
2g q24h 60.2 66.9 NA NA
ceftazidimec
1g q8h 75.6 72.4 NA 79.8
2g q8h 62.4 85.1 NA 85
2g q8h (3 hours) 95 88.7 NA 86.1
cefepimec
2g q12h 84.1 84.1 19.2 75.8
2g q8h 88.3 91.1 23.6 80
2g q8h (3 hours) 90.1 92.7 25.2 82
imipenemd
0.5g q8h 96.1 95.1 15.6 53.8
0.5g q6h 97.7 97.2 16 59.3
1g q8h 99.3 99.1 16.3 63.9
1g q8h (3 hours) 99.6 99.9 16.7 70.7
meropenemd
1g q8h 99.8 99.6 17 65.5
1g q8h (3 hours) 99.9 99.8 19.3 70.6
2g q8h 99.9 99.9 24.2 72.4
2g q8h (3 hours) 100 100 35.6 79.5
P. Koomanachai et al. / International Journal of Infectious Diseases 46 (2016) 22–2624*Probability of target attainment (PTA); In Monte Carlo simula-
tions, the probability that at least a speciﬁc value of a
pharmacodynamic index (e.g. 30% fT>MIC) is achieved at a certain
(minimum inhibitory) concentration.14
**The Cumulative fraction of response (CFR); the expected
population probability of target attainment for a speciﬁc drug
dose and a speciﬁc population of microorganisms.14
This study was approved by the Siriraj Institutional Review
Board.
3. Results
The MIC50, MIC90 and range of MICs for each of the study
antibiotics against the four Gram-negative bacteria are displayed
in Table 2. Against the Enterobacteriaceae the cephalosporin MICs
are shifted to the right indicating a loss of potency relative to that
of the carbapenems. Interpretation of these data according to the
current susceptibility breakpoints for the cephalosporins ranged
from 60% for ceftriaxone to 86% susceptible for cefepime, whereas
the carbapenems displayed >97% susceptibility (Table 3). As a
result of the MIC distributions for the E. coli and K. pneumoniae
among the cephalosporin treatments examined only the 2 g q8 h
regimens of ceftazidime and cefepime provided high CFRs
(Table 4). In contrast, all the carbapenem regimens displayed
CFRs >95% for these organisms.
When considering P. aeruginosa as the target pathogen,
cefepime and ceftazidime demonstrated higher % susceptibility
(82-83%) relative to that of the carbapenems (61-69%); however,
when considering the pharmacodynamic proﬁle and dosing
regimens only doripenem 2 g q8 h (4 h PI) achieved an optimal
CFR (92%) against this organism (Tables 3 and 4). As a result of the
low potency (i.e., susceptibilities of 16-22%) of all tested antibiotics
against A. baumannii, none of the cephalosporin or carbapenem
regimens investigated achieved CFRs > 65%.Table 2









DOR < 0.008 - 16 0.023 0.032
MEM 0.008 - 8 0.023 0.047
IPM 0.032 - 8 0.125 0.19
FEP 0.008 - > 256 0.032 16
CAZ 0.032 - > 256 0.19 32
CRO < 0.008 - 32 0.064 >32
E. coli
DOR 0.008 - 8 0.016 0.023
MEM 0.008 - 8 0.016 0.032
IPM 0.032 - 16 0.125 0.19
FEP < 0.008 - > 256 0.047 16
CAZ 0.016 - > 256 0.19 16
CRO < 0.008 - 32 0.064 >32
P. aeruginosa
DOR 0.016 - 32 0.25 >32
MEM 0.016 - 32 0.5 >32
IPM 0.064 - 32 1 >32
FEP 0.25 - > 256 1.5 >256
CAZ 0.5 - > 256 1 >256
A. baumannii
DOR 0.032 - 32 >32 >32
MEM 0.125 - 32 >32 >32
IPM 0.125 - 32 >32 >32
FEP 0.5 - > 256 64 >256
DOR; doripenem, MEM; meropenem, IPM; imipenem, FEP; cefepime, CAZ;
ceftazidime, CRO; ceftriaxone.
doripenemd
0.5g q8h (1 hour) 99.3 98.6 17.3 70
0.5g q8h (4 hours) 99.8 99.6 18.7 78.1
1g q8h (1 hour) 99.7 99.3 27 78.6
1g q8h (4 hours) 99.9 99.8 32.1 84.3
2g q8h (1 hour) 99.8 99.6 49.1 84.6
2g q8h (4 hours) 100 99.9 64.1 92.3
q_h = every __ hours.
a All antibiotics simulated as 0.5 hour infusions unless noted after dosing
regimen.
b CFR is reported as a percent of 5,000 simulated patients.
c Pharmacodynamic target was 50% freeT>MIC.
d Pharmacodynamic target was 40% freeT>MIC.
NA; Not appropriate to performed4. Discussion
Consistent with the increasing prevalence of drug-resistant
Gram-negative bacteria worldwide, the present study demon-
strated similar tendencies for E. coli, K. pneumoniae, A. baumannii,
and P. aeruginosa among isolates collected from patients admitted
to a large Thai teaching hospital. In the absence of novel antibiotics
with activity against such organisms, it is critical to understand
how dosing regimen selection may affect the ability of antibiotics
to achieve bactericidal exposure against pathogens with increasing
MICs. Herein, we present the results of a pharmacodynamic
proﬁling study designed to evaluate the currently available
intravenous b-lactam antibiotics against four of the most
frequently isolated Gram-negative organisms in the hospital
setting.
E. coli and K. pneumoniae displayed reduced susceptibility to the
most commonly utilized cephalosporins, ceftriaxone and ceftazi-
P. Koomanachai et al. / International Journal of Infectious Diseases 46 (2016) 22–26 25dime, while these organisms showed a much higher susceptibility
proﬁle to cefepime. While this observation might be due to the
higher intrinsic activity of cefepime, it should also be noted that
unlike ceftriaxone and ceftazidime, the institutional use of
cefepime at Siriraj hospital has been historically low due to the
higher acquisition cost of this product. Due to its reduced potency,
both the 1 and 2 g daily doses of ceftriaxone, the most commonly
utilized empirical treatment for suspected E. coli based infections
at the institution showed an unacceptably low CFR of 60%. Based
on the results of this pharmacodynamic analysis the use of
ceftriaxone for the empirical treatment of hospital-acquired
infection suspected to be due to E. coli should be avoided. As a
result of its potency and the use of an extended infusion time,
cefepime of 2 g every 8 h with 3-hour PI achieved optimal CFR
against both E. coli and K. pneumoniae (90% & 92%, respectively),
whereas a similar regimen of ceftazidime, 2 g every 8 h with 3-
hour PI, achieved sufﬁciently high CFRs only against E. coli. Unlike
the cephalosporins, all of the standard, high dosage & PI regimens
of carbapenems achieved optimal CFR against E. coli and K.
pneumoniae.
Unlike Enterobacteriaceae, the non-fermenters displayed a very
different pharmacodynamic proﬁle to the test agents investigated.
As would be expected from the MIC distribution of A. baumannii
against both the cephalosporin and the carbapenems, none of the
regimens examined in the present study produced optimal CFRs.
While the CFRs for the P. aeruginosa were higher than that observed
for A. baumannii, the most aggressive doing regimens of cefepime
and ceftazidime of 2 g every 8 h with 3-hour PI only approached
82 and 86%, respectively. When considering the carbapenems only
the doripenem dose of doripenem 2 g q8 h (4 h PI) delivered a CFR
above 90% for P. aeruginosa. These data highlight the challenges
facing clinicians when attempting to optimize the pharmacody-
namic proﬁle of these commonly utilized parenteral b-lactams
agents against these prominent nosocomial non-fermenting
Gram-negative pathogens.
The data derived from our current investigation are very similar
to the observations reported previously from the Asia-Paciﬁc
region regarding the both the Enterobacteriaceae and non-
fermenters.15 When speciﬁcally focusing on P. aeruginosa due to
the prevalence and multi-drug resistance proﬁle of this organism it
is important to note that only the high prolonged infusion dose of
doripenem reliably produce a CFR in excess of the 90% target
value.15
When considering the currently deﬁned b-lactam pharmaco-
dynamic proﬁles in this Thai tertiary care institution it is
interesting to note the resemblance of these data to not only that
of the Asia-Paciﬁc region but other analysis conducted using
isolates collected in Europe, South America and the United
States.15–19 When taken collectively these global data show that
the utilization of high dose b-lactams administered using the
prolonged infusion technique enhances the pharmacodynamic
proﬁle of all agents, however, it also displays the relatively poor
target attainment achieved for an increasing portion of the
organisms studied due to escalating resistance. While clinicians
should advocate for pharmacodynamically optimized regimens,
escalating MIC values are increasing circumventing this optimi-
zation process despite the utilization of high dose therapies.
While these Thai data appear to be similar to that reported from
across the globe, it must be recognized that data derived from this
university hospital or any other single institution may not be fully
representative of all institutions due to variations in the underlying
diagnosis or co-morbid conditions of the patients served as well as
antibiotic utilization. Additionally it should also be recognized that
the MICs derived in the current analysis were obtained from
clinical isolates sent to the laboratory for work-up without
differentiating between infection and colonization; however, thiscollection did represent a sample of organisms with the potential
to cause serious infections in the nosocomial setting.
In conclusion, while surveillance data may broadly guide the
physician to select more appropriate empirical antibiotic regimens
based on laboratory deﬁned criteria, pharmacodynamic assess-
ments such as the one derived from this Thai institution provide
additional insights into dosing strategies that may further
optimize drug exposure in an effort to maximize the probability
of microbiologic and clinical success. As such, the application of
known pharmacodynamic principles for the b-lactams should be
routinely utilized clinical practice when considering empiric
dosing regimens in an attempt to improve the probability of
treatment success for Gram-negative bacterial infections.
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